{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:05:39Z","timestamp":1791335139918,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell\u2019Aquila","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The present study investigated the combined effects of zofenoprilat (ZOFE) and nebivolol (NEBI) on endothelial function, focusing on their anti-inflammatory and antioxidant properties. The purpose was to evaluate whether these drugs, commonly used in clinical practice, offer a synergistic therapeutic strategy for managing hypertension and protecting vascular health. ZOFE, an ACE inhibitor, demonstrated significant anti-inflammatory activities by reducing inflammatory cytokines, thereby mitigating vascular inflammation, a key factor in hypertension and atherosclerosis. NEBI, a third-generation beta-blocker, exhibited strong antioxidant effects by enhancing nitric oxide (NO) levels, crucial for maintaining endothelial function and reducing oxidative stress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The potential effect of ZOFE and NEBI treatment was evaluated using human umbilical vein endothelial cells (HUVEC) as a model. Specifically, cells were challenged with tumor necrosis factor-\u03b1 (TNF-\u03b1) to induce endothelial dysfunction. Subsequently, cell viability, NO production, protein levels of superoxide dismutase (SOD) and catalase (CAT), enzymatic activity of SOD and CAT, intracellular levels of glutathione (GSH), inflammatory status, and levels of interleukin-6 (IL-6) monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory cytokine-1 (MIC-1), and the active form of nuclear factor kappa B (p-NF\u03baB), were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results showed that NEBI significantly counteracted oxidative stress, increasing the main antioxidant defenses (SOD, CAT, and GSH). The combination of ZOFE and NEBI resulted in a potentiated effect, enhancing both anti-inflammatory and antioxidant activities. This dual mechanism of action provides a comprehensive approach to protecting endothelial cells and improving vascular function. The combined therapy not only lowered blood pressure more effectively but also offered greater protection against endothelial damage compared to monotherapy with either drug alone. These findings suggest that the combination of ZOFE and NEBI could be particularly beneficial for patients with hypertension, especially those with coexisting inflammatory and oxidative stress-related conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This combination therapy, by addressing multiple pathogenic pathways simultaneously, could potentially be beneficial in patients with cardiovascular risk conditions. In conclusion, the combination of ZOFE and NEBI offers a potentially promising therapeutic approach for managing hypertension and protecting vascular health, aiming at improving clinical outcomes for patients with cardiovascular diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00833-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:51:45Z","timestamp":1770090705000},"page":"546-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potentiating anti-inflammatory and antioxidant effects in vitro: the combined action of zofenoprilat and nebivolol"],"prefix":"10.1007","volume":"78","author":[{"given":"Eleonora","family":"Maceroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"d\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Sofia","family":"Scenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suada","family":"Meto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fabrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"833_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/hr.2010.264","volume":"34","author":"R Rodrigo","year":"2011","unstructured":"Rodrigo R, Gonz\u00e1lez J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res. 2011;34:431\u201340. https:\/\/doi.org\/10.1038\/hr.2010.264.","journal-title":"Hypertens Res"},{"key":"833_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, Immunity, and hypertensive End-Organ damage. Circul Res. 2015;116:1022\u201333. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303697.","journal-title":"Circul Res"},{"key":"833_CR3","doi-asserted-by":"publisher","first-page":"1098725","DOI":"10.3389\/fimmu.2022.1098725","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol. 2022;13:1098725. https:\/\/doi.org\/10.3389\/fimmu.2022.1098725.","journal-title":"Front Immunol"},{"key":"833_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","volume":"54","author":"T M\u00fcnzel","year":"2009","unstructured":"M\u00fcnzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.066.","journal-title":"J Am Coll Cardiol"},{"key":"833_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2165\/00044011-200727120-00006","volume":"27","author":"AC Schmidt","year":"2007","unstructured":"Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27:841\u20139. https:\/\/doi.org\/10.2165\/00044011-200727120-00006.","journal-title":"Clin Drug Investig"},{"key":"833_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1185\/03007990903533681","volume":"26","author":"VA Fonseca","year":"2010","unstructured":"Fonseca VA. Effects of \u03b2-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26:615\u201329. https:\/\/doi.org\/10.1185\/03007990903533681.","journal-title":"Curr Med Res Opin"},{"key":"833_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/0003319713489340","volume":"65","author":"M Karabacak","year":"2014","unstructured":"Karabacak M, Dogan A, Aksoy F, Ozaydin M, Erdogan D, Karabacak P. Both carvedilol and nebivolol May improve platelet function and prothrombotic state in patients with nonischemic heart failure. Angiology. 2014;65:533\u20137. https:\/\/doi.org\/10.1177\/0003319713489340.","journal-title":"Angiology"},{"key":"833_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1074248415581175","volume":"21","author":"V Ignjatovic","year":"2016","unstructured":"Ignjatovic V, Pavlovic S, Miloradovic V, Andjelkovic N, Davidovic G, Djurdjevic P, et al. Influence of different \u03b2-Blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy. J Cardiovasc Pharmacol Ther. 2016;21:44\u201352. https:\/\/doi.org\/10.1177\/1074248415581175.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"833_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fca-2021-0048","volume":"17","author":"C Ferri","year":"2021","unstructured":"Ferri C. The role of nebivolol in the management of hypertensive patients: from Pharmacological profile to treatment guidelines. Future Cardiol. 2021;17:1421\u201333. https:\/\/doi.org\/10.2217\/fca-2021-0048.","journal-title":"Future Cardiol"},{"key":"833_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41:1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"key":"833_CR11","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"833_CR12","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme Inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461.","journal-title":"Circulation"},{"key":"833_CR13","doi-asserted-by":"publisher","first-page":"305087","DOI":"10.1155\/2008\/305087","volume":"2008","author":"G Desideri","year":"2008","unstructured":"Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. https:\/\/doi.org\/10.1155\/2008\/305087.","journal-title":"Mediators Inflamm"},{"key":"833_CR14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1080\/03007995.2022.2096352","volume":"38","author":"M Volpe","year":"2022","unstructured":"Volpe M, Pegoraro V, Peduto I, Heiman F, Meto S. Extemporaneous combination therapy with nebivolol\/zofenopril in hypertensive patients: usage in Italy. Curr Med Res Opin. 2022;38:1673\u201381. https:\/\/doi.org\/10.1080\/03007995.2022.2096352.","journal-title":"Curr Med Res Opin"},{"key":"833_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40659-023-00438-1","volume":"56","author":"A Antonosante","year":"2023","unstructured":"Antonosante A, Castelli V, Sette M, Alfonsetti M, Catanesi M, Benedetti E, et al. Neuroprotective effects of the PPAR\u03b2\/\u03b4 antagonist GSK0660 in in vitro and in vivo parkinson\u2019s disease models. Biol Res. 2023;56:27. https:\/\/doi.org\/10.1186\/s40659-023-00438-1.","journal-title":"Biol Res"},{"key":"833_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41419-022-04964-w","volume":"13","author":"L Brandolini","year":"2022","unstructured":"Brandolini L, d\u2019Angelo M, Novelli R, Castelli V, Giorgio C, Sirico A, et al. Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death Dis. 2022;13:500. https:\/\/doi.org\/10.1038\/s41419-022-04964-w.","journal-title":"Cell Death Dis"},{"key":"833_CR17","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1172\/JCI119868","volume":"100","author":"A Papapetropoulos","year":"1997","unstructured":"Papapetropoulos A, Garc\u00eda-Carde\u00f1a G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 1997;100:3131\u20139. https:\/\/doi.org\/10.1172\/JCI119868.","journal-title":"J Clin Invest"},{"key":"833_CR18","doi-asserted-by":"publisher","first-page":"E135","DOI":"10.1017\/S002966511700297X","volume":"76","author":"M Le Sayec","year":"2017","unstructured":"Le Sayec M, Serreli G, Thou E, Lacour C, Spencer JPE, Corona G. Ferulic acid and its derivatives modulate nitric oxide balance in HUVEC cells. Proc Nutr Soc. 2017;76:E135. https:\/\/doi.org\/10.1017\/S002966511700297X.","journal-title":"Proc Nutr Soc"},{"key":"833_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3892\/or.2012.1842","volume":"28","author":"WH Park","year":"2012","unstructured":"Park WH, Kim SH. Involvement of reactive oxygen species and glutathione in Gallic acid-induced human umbilical vein endothelial cell death. Oncol Rep. 2012;28:695\u2013700. https:\/\/doi.org\/10.3892\/or.2012.1842.","journal-title":"Oncol Rep"},{"key":"833_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/emmm.201000080","volume":"2","author":"A Benigni","year":"2010","unstructured":"Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247\u201357. https:\/\/doi.org\/10.1002\/emmm.201000080.","journal-title":"EMBO Mol Med"},{"key":"833_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-981-97-7380-0_7","volume-title":"Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers [Internet]","author":"M Nandave","year":"2024","unstructured":"Nandave M. Immunomodulator activity of ACE inhibitors and angiotensin receptor blockers in hypertensive patients. In: Nandave M, editor. Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers [Internet]. Singapore: Springer Nature Singapore; 2024. pp. 329\u201376. [cited 2025 Feb 13]. https:\/\/doi.org\/10.1007\/978-981-97-7380-0_7."},{"key":"833_CR22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1134\/S0006297916110134","volume":"81","author":"AR Fatkhullina","year":"2016","unstructured":"Fatkhullina AR, Peshkova IO, Koltsova EK. The role of cytokines in the development of atherosclerosis. Biochem (Mosc). 2016;81:1358\u201370. https:\/\/doi.org\/10.1134\/S0006297916110134.","journal-title":"Biochem (Mosc)"},{"key":"833_CR23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/HYPERTENSIONAHA.124.21712","volume":"81","author":"RR Dos Passos","year":"2024","unstructured":"Dos Passos RR, Santos CV, Priviero F, Briones AM, Tostes RC, Webb RC, et al. Immunomodulatory activity of cytokines in hypertension: A vascular perspective. Hypertension. 2024;81:1411\u201323. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.21712.","journal-title":"Hypertension"},{"key":"833_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/00005344-200009000-00006","volume":"36","author":"LA Altwegg","year":"2000","unstructured":"Altwegg LA, d\u2019Uscio LV, Barandier C, Cosentino F, Yang Z, L\u00fcscher TF. Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. J Cardiovasc Pharmacol. 2000;36:316\u201320. https:\/\/doi.org\/10.1097\/00005344-200009000-00006.","journal-title":"J Cardiovasc Pharmacol"},{"key":"833_CR25","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1161\/CIRCULATIONAHA.105.556233","volume":"112","author":"RP Mason","year":"2005","unstructured":"Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795\u2013801. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.556233.","journal-title":"Circulation"},{"key":"833_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3349\/ymj.2012.53.2.258","volume":"53","author":"S Park","year":"2012","unstructured":"Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53:258. https:\/\/doi.org\/10.3349\/ymj.2012.53.2.258.","journal-title":"Yonsei Med J"},{"key":"833_CR27","doi-asserted-by":"publisher","first-page":"1500882","DOI":"10.3389\/fcvm.2025.1500882","volume":"12","author":"Z Yu","year":"2025","unstructured":"Yu Z, Gao J, Zhou Z, Li L, Hu S. Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis. Front Cardiovasc Med. 2025;12:1500882. https:\/\/doi.org\/10.3389\/fcvm.2025.1500882.","journal-title":"Front Cardiovasc Med"},{"key":"833_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tiv.2005.03.009","volume":"19","author":"CR Partridge","year":"2005","unstructured":"Partridge CR, Johnson CD, Ramos KS. In vitro models to evaluate acute and chronic injury to the heart and vascular systems. Toxicol in Vitro. 2005;19:631\u201344. https:\/\/doi.org\/10.1016\/j.tiv.2005.03.009.","journal-title":"Toxicol in Vitro"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00833-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00833-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00833-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:35:02Z","timestamp":1773196502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00833-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00833-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"We confirm that neither the manuscript nor any parts of its content are currently under consideration for publication or published in another journal. All authors have approved the manuscript and agree with its submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors E.M., A.C., M.d.A., M.S.S., and V.C. declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. S.M., S.B. and P.F. declare the following financial interests which may be considered as potential competing interests: are employees of Menarini Group. G.D. has a consultancy agreement with Menarini Group and has been the PI for Menarini Clinical Trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}